ClinicalTrials.gg
CompletedNCT00495313Updated Dec 16, 2008

Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens

A Phase 4 interventional study of doxycycline and doxycycline in Rosacea, sponsored by CollaGenex Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-12-16.

Sponsored by CollaGenex Pharmaceuticals (part of Galderma Group AG) · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.

Enrollment
8th of 12
91 · median 150
Started
2007
the only one that year
Phase 4
6 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
3 of 12
CollaGenex Pharmaceuticals

Among the 12 studies testing doxycycline in Rosacea, this one is the 8th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 4, and was the 3rd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing doxycycline in Rosacea as a file.
02

Study summary

To compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%

Read the detailed description

Compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%

03

Conditions studied

  • Rosacea

Browse trials for

Keywords

  • Rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 8-40 total lesions
  • erythema
  • telangiectasia

Exclusion criteria

Exclusion Criteria:

  • non-pregnant, non-lactating
  • achlorhydric
  • gastric by-pass surgery
  • allergy to study medications
  • drug/alcohol abuse
  • use of proton pump inhibitors
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Active comparator
    Cohort 1: doxycycline

    Vibramycin plus metronidazole

    Drug: doxycycline

  • Active comparator
    Cohort 2

    Oracea® delayed release plus metronidazole

    Drug: doxycycline

Interventions

  • COL-101, QD plus metronidazole

    Also known as: Vibramycin, 100 mg, QD plus metornidazole

  • 40 mg with metronidazole QD

    Also known as: Oracea® 40 mg plus metronidazole

06

What researchers measure

Primary outcomes

  1. Change in total lesion count from Baseline at the study endpoint

    Time frame: 16 weeks

Secondary outcomes

  1. Change in Investigator's Global Assessment from Baseline at the study endpoint

    Time frame: 16 weeks

  2. Change in Clinician's Erythema Assessment score from Baseline at the study endpoint

    Time frame: 16 weeks

  3. Change in total lesion count (papules + pustules + nodules) from Baseline at each visit

    Time frame: 4 weeks, 8 weeks, 12 weeks

07

Study locations

7 sites
  • Joel Schlessinger
    Omaha, Nebraska 68144, United States
  • James Del Rosso
    Las Vegas, Nevada 89052, United States
  • Angela Moore
    Arlington, Texas 76011, United States
  • William Abramovits
    Dallas, Texas 75230, United States
  • Douglas Forsha
    West Jordan, Utah 84088, United States
  • Bernard Goffe
    Seattle, Washington 98101, United States
  • William Werschler
    Spokane, Washington 99204, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2007
First posted
Jul 3, 2007
Start
Mar 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Dec 16, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00495313
First posted
Jul 3, 2007
Start date
Mar 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Dec 16, 2008

Study contacts

Christopher V Powala, JD
study chair · CollaGenex Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion